Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trials

NewsGuard 100/100 Score

Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design. Genomics plc is a global leader in PRS-powered technologies and approaches and has developed extensive genetic databases and algorithms to understand the genetic component of diseases.

Genomics plc and GSK will investigate several applications for Genomics’ suite of PRS-powered tools, including the potential for PRS tools to reduce the number of trial participants and shortening study timescales and improving outcomes of both proof-of-concept and pivotal trials.

We could not be more excited to be collaborating with GSK on this programme. PRS-based approaches have the potential to support clinical trial design. Using PRS to get the right people into studies could have a potential positive impact, including in the reduction of trial size and timescale, leading to efficiencies in drug development.”

Professor Sir Peter Donnelly FRS, FMedSci, Founder and Chief Executive Officer, Genomics plc

Genetic factors play a key role in disease susceptibility, progression, and response to drugs. These effects are often a result of many thousands of genetic changes that can be captured as a single number or PRS. This work will explore the opportunity for PRS-based approaches to support patient selection, and understand how that may impact clinical trials through reducing the number of patients recruited or shortening the duration of trials.

Robert Scott, Vice President of Human Genetics and Genomics at GSK: “Genomics plc is leading in both the development and real-world application of PRS-based approaches, opening up new frontiers in genomic medicine. At GSK, we have demonstrated the opportunity for genetics to guide drug discovery and development; I look forward to working with Genomics plc to further explore the potential for PRS to support clinical trial design.”


Genomics plc


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ERS Genomics and IRBM sign CRISPR/Cas9 license agreement